問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Urology

Division of Thoracic Medicine

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Hematology & Oncology

National Taiwan University Cancer Center (在職)

Division of Hematology & Oncology

Division of Hematology & Oncology

更新時間：2025-09-17

林家齊Lin, Chia-Chi
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

Recruiting Trial

377Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林家齊

List

688Cases

2019-03-15 - 2021-03-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Not yet recruiting1Sites

2021-05-10 - 2023-10-06

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2021-07-01 - 2022-08-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting2Sites

Terminated1Sites

2015-07-01 - 2020-12-31

Phase II

Multicenter, open-label, single arm, Phase II study in advanced non-small cell lung cancer；Subtitle:A multicenter, open-label, single arm Phase II study to evaluate safety and efficacy of ONO-4538 in stage IIIB/IV or recurrent non-small cell lung cancer patients who are unsuited to radical radiotherapy and resistant to a platinum-base chemotherapeutic regimen.

  • Condition/Disease

    stage IIIB/IV or recurrent non-small cell lung cancer

  • Test Drug

    Opdivo®

Participate Sites
10Sites

Not yet recruiting1Sites

Terminated8Sites

陳育民
Taipei Veterans General Hospital

Division of Thoracic Medicine

楊政達
Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

2020-04-01 - 2024-03-15

Phase I/II

A Phase I, Open-Label, Multi-Center, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer

  • Condition/Disease

    Advanced Solid Tumorsand/ Small Cell Lung Cancer

  • Test Drug

    IMP4297 and Temozolomide

Participate Sites
4Sites

Recruiting4Sites

2019-05-01 - 2025-12-31

Phase I/II

Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer

  • Condition/Disease

    Advance tumor

  • Test Drug

    FLX475

Participate Sites
4Sites

Recruiting4Sites

2022-01-01 - 2025-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2023-05-01 - 2025-12-31

Phase I

An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors

  • Condition/Disease

    Solid Tumor

  • Test Drug

    IDE397

Participate Sites
2Sites

Recruiting2Sites

2010-08-01 - 2012-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2015-03-01 - 2018-02-28

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

1 41 42 43 44 45 69
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB